Literature DB >> 7921606

Actions of two new antagonists showing selectivity for different sub-types of metabotropic glutamate receptor in the neonatal rat spinal cord.

D E Jane1, P L Jones, P C Pook, H W Tse, J C Watkins.   

Abstract

1. The presynaptic depressant action of L-2-amino-4-phosphonobutyrate (L-AP4) on the monosynaptic excitation of neonatal rat motoneurones has been differentiated from the similar effects produced by (1S,3R)-1-aminocyclopentane-1,3-dicarboxylate ((1S,3R)-ACPD), (1S,3S)-ACPD and (2S,3S,4S)-alpha-(carboxycyclopropyl)glycine (L-CCG-I), and from the postsynaptic motoneuronal depolarization produced by (1S,3R)-ACPD, by the actions of two new antagonists, alpha-methyl-L-AP4 (MAP4) and alpha-methyl-L-CCG-I (MCCG). Such selectivity was not seen with a previously reported antagonist, (+)-alpha-methyl-4-carboxyphenylglycine (MCPG). 2. MAP4 selectively and competitively antagonized the depression of monosynaptic excitation produced by L-AP4 (KD 22 microM). At ten fold higher concentrations, MAP4 also antagonized synaptic depression produced by L-CCG-I but in an apparently non-competitive manner. MAP4 was virtually without effect on depression produced by (1S,3R)- or (1S,3S)-ACPD. 3. MCCG differentially antagonized the presynaptic depression produced by the range of agonists used. This antagonist had minimal effect on L-AP4-induced depression. The antagonism of the synaptic depression effected by (1S,3S)-ACPD and L-CCG-I was apparently competitive in each case but of varying effectiveness, with apparent KD values for the interaction between MCCG and the receptors activated by the two depressants calculated as 103 and 259 microM, respectively. MCCG also antagonized the presynaptic depression produced by (1S,3R)-ACPD. 4. Neither MAP4 nor MCCG (200-500 microM) significantly affected motoneuronal depolarizations produced by (1S,3R)-ACPD. At the same concentrations the two antagonists produced only very weak and variable effects (slight antagonism or potentiation) on depolarizations produced by (S)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and N-methyl-D-aspartate (NMDA).5. It is concluded that MAP4 is a potent and selective antagonist for those excitatory amino acid(EAA) receptors on neonatal rat primary afferent terminals that are preferentially activated by L-AP4,and that MCCG is a relatively selective antagonist for different presynaptic EAA receptors that are preferentially activated by (1S,3S)-ACPD and (perhaps less selectively) by L-CCG-I. These receptors probably comprise two sub-types of metabotropic glutamate receptors negatively linked to adenylyl cyclase activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7921606      PMCID: PMC1910212          DOI: 10.1111/j.1476-5381.1994.tb13151.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

Review 1.  Metabotropic glutamate receptors in brain function and pathology.

Authors:  D D Schoepp; P J Conn
Journal:  Trends Pharmacol Sci       Date:  1993-01       Impact factor: 14.819

2.  Antagonism of presynaptically mediated depressant responses and cyclic AMP-coupled metabotropic glutamate receptors.

Authors:  M Kemp; P Roberts; P Pook; D Jane; A Jones; P Jones; D Sunter; P Udvarhelyi; J Watkins
Journal:  Eur J Pharmacol       Date:  1994-01-15       Impact factor: 4.432

3.  Evidence for presynaptic depression of monosynaptic excitation in neonatal rat motoneurones by (1S,3S)- and (1S,3R)-ACPD.

Authors:  P C Pook; D C Sunter; P M Udvarhelyi; J C Watkins
Journal:  Exp Physiol       Date:  1992-05       Impact factor: 2.969

4.  The effects of a series of omega-phosphonic alpha-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations.

Authors:  R H Evans; A A Francis; A W Jones; D A Smith; J C Watkins
Journal:  Br J Pharmacol       Date:  1982-01       Impact factor: 8.739

5.  Phenylglycine derivatives as new pharmacological tools for investigating the role of metabotropic glutamate receptors in the central nervous system.

Authors:  E F Birse; S A Eaton; D E Jane; P L Jones; R H Porter; P C Pook; D C Sunter; P M Udvarhelyi; B Wharton; P J Roberts
Journal:  Neuroscience       Date:  1993-02       Impact factor: 3.590

6.  Signal transduction, pharmacological properties, and expression patterns of two rat metabotropic glutamate receptors, mGluR3 and mGluR4.

Authors:  Y Tanabe; A Nomura; M Masu; R Shigemoto; N Mizuno; S Nakanishi
Journal:  J Neurosci       Date:  1993-04       Impact factor: 6.167

Review 7.  Molecular diversity of glutamate receptors and implications for brain function.

Authors:  S Nakanishi
Journal:  Science       Date:  1992-10-23       Impact factor: 47.728

8.  Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine and (RS)-alpha-methyl-4-carboxyphenylglycine.

Authors:  S A Eaton; D E Jane; P L Jones; R H Porter; P C Pook; D C Sunter; P M Udvarhelyi; P J Roberts; T E Salt; J C Watkins
Journal:  Eur J Pharmacol       Date:  1993-01-15       Impact factor: 4.432

9.  A family of metabotropic glutamate receptors.

Authors:  Y Tanabe; M Masu; T Ishii; R Shigemoto; S Nakanishi
Journal:  Neuron       Date:  1992-01       Impact factor: 17.173

10.  3,5-Dihydroxyphenyl-glycine: a potent agonist of metabotropic glutamate receptors.

Authors:  I Ito; A Kohda; S Tanabe; E Hirose; M Hayashi; S Mitsunaga; H Sugiyama
Journal:  Neuroreport       Date:  1992-11       Impact factor: 1.837

View more
  20 in total

1.  Developmental regulation of hippocampal excitatory synaptic transmission by metabotropic glutamate receptors.

Authors:  F M Ross; J Cassidy; M Wilson; S N Davies
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

2.  Activation of group I metabotropic glutamate receptors depresses recurrent inhibition of motoneurons in the neonatal rat spinal cord in vitro.

Authors:  Cristina Marchetti; Giuliano Taccola; Andrea Nistri
Journal:  Exp Brain Res       Date:  2005-07-01       Impact factor: 1.972

3.  Impaired cerebellar synaptic plasticity and motor performance in mice lacking the mGluR4 subtype of metabotropic glutamate receptor.

Authors:  R Pekhletski; R Gerlai; L S Overstreet; X P Huang; N Agopyan; N T Slater; W Abramow-Newerly; J C Roder; D R Hampson
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

4.  Metabotropic glutamate receptors promote disinhibition of olfactory bulb glomeruli that scales with input strength.

Authors:  Joseph D Zak; Jennifer D Whitesell; Nathan E Schoppa
Journal:  J Neurophysiol       Date:  2014-12-31       Impact factor: 2.714

Review 5.  Group III metabotropic glutamate receptors: pharmacology, physiology and therapeutic potential.

Authors:  Marion S Mercier; David Lodge
Journal:  Neurochem Res       Date:  2014-08-22       Impact factor: 3.996

Review 6.  Synaptic control of motoneuronal excitability.

Authors:  J C Rekling; G D Funk; D A Bayliss; X W Dong; J L Feldman
Journal:  Physiol Rev       Date:  2000-04       Impact factor: 37.312

7.  Stimulation of microglial metabotropic glutamate receptor mGlu2 triggers tumor necrosis factor alpha-induced neurotoxicity in concert with microglial-derived Fas ligand.

Authors:  Deanna L Taylor; Fleur Jones; Eva S F Chen Seho Kubota; Jennifer M Pocock
Journal:  J Neurosci       Date:  2005-03-16       Impact factor: 6.167

8.  Stimulatory effects of the putative metabotropic glutamate receptor antagonist L-AP3 on phosphoinositide turnover in neonatal rat cerebral cortex.

Authors:  R Mistry; G Prabhu; M Godwin; R A Challiss
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

9.  Mechanisms involved in the metabotropic glutamate receptor-enhancement of NMDA-mediated motoneurone responses in frog spinal cord.

Authors:  A M Holohean; J C Hackman; R A Davidoff
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

10.  Actions of LY341495 on metabotropic glutamate receptor-mediated responses in the neonatal rat spinal cord.

Authors:  Patrick A Howson; David E Jane
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.